𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

✍ Scribed by Ma, W W; Villaroel, M C; Zhao, M; Rajeshkumar, N V; Jimeno, A; Donehower, R; Garrido-Laguna, I; Tan, A C; Uson, M; Angenendt, M

Book ID
110000608
Publisher
Nature Publishing Group
Year
2010
Tongue
English
Weight
434 KB
Volume
103
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Preclinical and clinical evaluation of p
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
✍ Julian Adams πŸ“‚ Article πŸ“… 2002 πŸ› Elsevier Science 🌐 English βš– 824 KB

The proteasome is a multicatalytic protease, present in all eukaryotic cells, that is primarily responsible for intracellular protein degradation. By destroying regulatory proteins or their inhibitors, the proteasome influences many cellular regulatory signals and is thus a potential target for phar

In vivo antitumor effect of the mTOR inh
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer
✍ Daisuke Ito; Koji Fujimoto; Tomohiko Mori; Kazuhiro Kami; Masayuki Koizumi; Eiji πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 459 KB

## Abstract Mammalian target of rapamycin (mTOR) is considered to be a major effector of cell growth and proliferation that controls protein synthesis through a large number of downstream targets. We investigated the expression of the phosphatidylinositol 3′‐kinase (PI3K)/mTOR signaling pathway in